Geovax Labs Inc
Followers: 256 Since 1/15/2020
and here comes the truth: from the LAST (repeat LAST filing, not from October 2019 as posted below).
I won't speculate why this manipulation below....No Comment
Item 5.07 Submission of Matters to a Vote of Security Holders. We held a special meeting of stockholders on January 3, 2020. We received proxies for 586,811,868 shares (approximately 86.5%) of our issued and outstanding
shares of common stock, as of the record date of November 21,
AS OF 10/25/2019
will update as changes happen
Market Cap 274,624 (per OTCMarkets 10/24/2019)
A/S - 600M as stated in latest 8k and OTCMarkets (10/08/19)
O/S - 96M as stated in latest 8k - 137M as stated on OTCMarkets (10/08/19)
Float - 106M (per OTCMarkets 10/02/19)
as we have many discussion here about whether convertible is done or not, here are the calculation based on official trading volumes as reported by yahoofinance , from 1. October till now (after Geovax last update). The calculations are based on the volume and HIGHEST price per day (not 80% of price), given that ALL the volume would have come from conversion (which is almost impossible).
11. October: volume 78.520.447,0000, highest price: 0,0020, USD value: 157.040,89
10. October: volume 67.022.024,0000, highest price: 0,0030, USD value 201.066,07
9. October: volume: 102.821.930,0000, highest price:0,0043, USD value: 442.134,30
8 October: volume: 60.294.478,0000, highest price:0,0027, USD value: 162.795,09
7. October: volume: 52.257.646,0000, highest price:0,0020, USD value: 104.515,29
1. October: volume: 48.591.000,0000, highest price:0,0100, USD value: 485.910,00
total USD: 1.553.461,65
total shares 409.507.525+95.627.584 million as reported for 30th Sep= approx. 505 million shares
if the assumptions to "all valume comes from conversion" were true, it is 50% of outstanding convertible, with more than 500 million outstanding shares by now.
GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.
Our proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), and Emory University. Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.
Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa) and Zika virus. We also have initiated programs to develop a vaccine to treat chronic Hepatitis B infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our product. Our hemorrhagic fever vaccine program was initiated during 2014 in response to the Ebola epidemic in western Africa and with the goal of developing second generation monovalent and multivalent vaccines capable of preventing or containing future outbreaks of major hemorrhagic fever viruses indigenous to Africa. Our initial preclinical studies in rodents and nonhuman primates for our first vaccine candidate (Ebola-Zaire virus) have shown 100% protection against death after a single dose. Our most advanced vaccines under development are designed to function against the clade B subtype of the HIV virus that is prevalent in the Americas and Western Europe. Our preventive clade B HIV vaccine has successfully completed Phase 2a human clinical testing has entered a follow-on clinical trial in 2017. Our clade B vaccine has shown outstanding safety and excellent, highly reproducible immunogenicity. We are extending our HIV vaccine effort to the most common virus subtype affecting the developing world, clade C. We also are investigating our HIV vaccines for their potential to contribute to combination therapies leading to a cure for HIV infections.
Our vaccine technology was developed in collaboration with researchers at Emory University, the NIH, and the CDC. The technology is exclusively licensed to us from Emory University. We also have nonexclusive licenses to certain patents owned by the NIH. Our hemorrhagic fever vaccines have been developed with technology licensed from, and in collaboration with, the NIH. Our immuno-oncology program is being developed pursuant to a research collaboration with the University of Pittsburgh. Our Zika vaccine program is in collaboration with University of Georgia and the CDC. Our HBV therapeutic program is in collaboration with Georgia State University and our malaria vaccine is being developed in collaboration with Burnet Institute in Australia.
Our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants awarded directly to us, in kind support in terms of animal experiments, as well as indirect support for the conduct of our human clinical trials. All of the human clinical trials of our preventative vaccines to date have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).
We know our work could affect the lives of millions worldwide, and we invite you to join our effort.
Robert McNally, CEO of GeoVax Labs Inc.,
Zika vaccine developer names new chief scientific officer
Jan 3, 2017, 10:51am EST Updated Jan 4, 2017, 11:59pm EST
Get Atlanta Newsletters and Aler
Morning Edition >> Afternoon Edit
Enter your email address
SignA Smyrna-based developer of vac A Smyrna-based developer of vaccines against Zika, Ebola, HIV and other infectious diseases has named a new chief scientific officer.
Farshad Guirakhoo was promoted to the C-suite role at GeoVax Labs Inc. from senior vice president of research and development, his title upon joining the company in 2015. The promotion was effective Jan. 1.
His predecessor as CSO, company co-founder Harriet L. Robinson, will remain as chief scientific officer emeritus, the company said in a statement.
"For the past year, Farshad has been a driving force behind the growth of our vaccine development pipeline, and we are pleased to expand his role at this critical time for our company," GeoVax President and CEO Robert T. McNallysaid in the statement. "In the role of Chief Scientific Officer, Dr. Guirakhoo will lead the scientific advancement of GeoVax's technology pipeline as the Company identifies and pursues new opportunities to address significant medical needs."
Robinson will continue to direct the company's HIV vaccine program and to serve as principal investigator on National Institutes of Health grants to GeoVax, McNally said. Robinson will also continue to serve as a member of the GeoVax Board of Directors.
Before joining GeoVax in 2015, Guirakhoo served in senior management and scientific roles with biotechnology companies included Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis Inc. and OraVax Inc. He earned his Ph.D. in virology at the Medical University of Vienna in Vienna, Austria, and he holds a M.Sc. degree in genetics and a B.Sc. degree in biology. His post-doctoral training included a stint at the Centers for Disease Control and Prevention'sDivision of Vector-Borne Infectious Diseases in Fort Collins, Colo. Guirakhoo has filed over 90 patent applications in his scientific career, according to the statement, and was instrumental in the development and commercialization of the Imojev Japanese encephalitis virus vaccine and the Dengvaxia vaccine for Dengue virus.
GeoVax Labs Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases. Its development programs are focused on vaccines against HIV, Zika, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa).
In February 2016, The University of Georgia and GeoVax announced a collaboration to develop and test a possible Zika virus vaccine.
Vaccines typically contain agents (antigens) that resemble disease-causing microorganisms. Traditional vaccines are often made from weakened or killed forms of the virus or from its surface proteins. Many newer vaccines use recombinant DNA (deoxyribonucleic acid) technology to generate vaccine antigens in bacteria or cultured cells from specific portions of the DNA sequence of the target pathogen. The generated antigens are then purified and formulated for use in a vaccine. The most successful of these purified antigens have been non-infectious virus-like particles (VLPs) as exemplified by vaccines for hepatitis B (Merck's Recombivax® and GSK's Engerix®) and Papilloma viruses (GSK's Cervarix®, and Merck's Gardasil®). Our approach uses recombinant DNA or recombinant viruses to produce VLPs in the person being vaccinated. In human clinical trials of our HIV vaccines, we have demonstrated that our VLPs, expressed in the cells of the person being vaccinated, are safe, yet elicit both strong and durable humoral and cellular immune response.
VLPs train the body's immune system to recognize and kill the authentic virus should it appear. VLPs also train the immune system to recognize and kill infected cells to control infection and reduce the length and severity of disease. One of the biggest challenges with VLP-based vaccines is to design the vaccines in such a way that the VLPs will be recognized by the immune system in the same way as the authentic virus would be. When VLPs for enveloped viruses like HIV, Ebola, Marburg or Lassa fever are produced in vivo, they include not only the protein antigens, but also an envelope consisting of membranes from the vaccinated individual's cells. In this way, they are highly similar to the virus generated in a person's body during a natural infection. VLPs produced externally, by contrast, have no envelope; or, envelopes from the cultured cells (typically hamster or insect cells) used to produce them. We believe our technology provides distinct advantages by producing VLPs that more closely resemble the authentic virus, which in turn, allows the body's immune system to more readily recognize the authentic virus. By producing VLPs in vivo, we avoid potential purification issues associated with in vitro production of VLPs.
Ebola VLPs HIV VLPs
Electron micrographs showing the VLPs elicited by GeoVax vaccines from human cells. Note that the Ebola VLPs on the left self-assemble into the rod-like shape of the authentic Ebola virus, while the HIV VLPs shown on the right take on the spherical shape of the authentic HIV virus. While below the resolution of these micrographs, both types of VLPs display what we believe to be the native form of their respective viral envelope glycoproteins which we believe is key to generating an effective immune humoral response.
Our MVA-VLP vector affords other unique advantages:
Safety: GeoVax/NIAID rMVA HIV vaccines have demonstrated outstanding safety in human clinical trials. Safety for MVA has been shown in more than 120,000 subjects in Europe, including immunocompromised individuals during the initial development of MVA and more recently with the development of MVA as a safer vaccine against smallpox.
Durability: GeoVax/NIAID rMVA technology raises highly durable vaccine responses, the most durable in the field of vectored HIV vaccines. We hypothesize that elicitation of durable vaccine responses is conferred on responding B cells by the vaccinia parent of MVA, which raises highly durable responses for smallpox.
Limited pre-existing immunity to vector: Following the eradication of smallpox in 1980, smallpox vaccinations subsequently ended, leaving all but those born before 1980 and selected populations (such as vaccinated laboratory workers, first responders) unvaccinated and without pre-existing immunity.
No need for adjuvants: MVA stimulates strong innate immune responses and does not require the use of adjuvants.
Thermal stability: MVA is stable in both liquid and lyophilized formats (> 6 years of storage).
Genetic stability and manufacturability: If appropriately engineered, MVA is genetically stable and can reliably be manufactured in either the established Chick Embryo Fibroblast cell substrate, or novel continuous cell lines that support scalability as well as greater process consistency and efficiency.
GOVX Zika Quicklinks: Breaking News
March ,2017 https://finance.yahoo.com/news/geovax-reports-vaccine-development-progress-130000086.html
March, 2017 https://www.geovax.com/news/entry/2017/03/20/geovax-reports-promising-results-for-zika-vaccine.html
March, 2017 https://www.geovax.com/news/entry/2017/03/14/geovax-announces-collaboration-with-american-gene-technologies-for-hiv-functional-cure.html
Febuary , 2017 https://www.geovax.com/news/entry/2017/02/02/geovax-media-and-presentation-update.html
January, 2017 https://www.geovax.com/news/entry/2017/01/23/geovax-announces-initiation-of-hiv-human-clinical-trial.html
January, 2017 https://www.geovax.com/news/entry/2017/01/17/geovax-to-collaborate-with-georgia-state-university-on-development-of-therapeutic-hepatitis-b-vaccine.html
October, 2016 GeoVax to Present at Upcoming Scientific Conferences on its Hemorrhagic Fever and Zika Vaccine Programs
June, 2016 GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting
June, 2016 GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
May, 2016 GeoVax Presents at Zika Virus Scientific Conference
April, 2016 GeoVax Provides Update on Zika Vaccine Program
March, 2016 GeoVax Extends Research Collaborations on Zika Vaccine
March, 2016 GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
February, 2016 GeoVax to Develop Vaccine Against Zika Virus
Long Speculation on GOVX's Zika Vaccine: On November 6, 2016, 60 Minutes did a segment titled: The Zika Virus
. The pieced highlighted a Zika vaccine platform that appears to be proving successful. The platform described is similar to that of GOVX' s Intellectual Property
. Other connections include a CDC sponsorship & Emory University. No definitive evidence has been disclosed.